Get the Stockscreener App
0.2103
1.87%
-0.004
Pre-market:
.21
-0.0003
-0.14%
Processa Pharmaceuticals Inc stock is traded at $0.2103, with a volume of 3.13M.
It is down -1.87% in the last 24 hours and down -3.53% over the past month.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
See More
Previous Close:
$0.2143
Open:
$0.2185
24h Volume:
3.13M
Relative Volume:
0.57
Market Cap:
$10.59M
Revenue:
-
Net Income/Loss:
$-11.53M
P/E Ratio:
-0.0436
EPS:
-4.82
Net Cash Flow:
$-11.12M
1W Performance:
+1.69%
1M Performance:
-3.53%
6M Performance:
-52.04%
1Y Performance:
-84.28%
1-Day Range:
$0.2027
$0.2225
1-Week Range:
$0.1896
$0.2265
52-Week Range:
$0.15
$1.50
Processa Pharmaceuticals Inc Stock (PCSA) Company Profile
Name
Processa Pharmaceuticals Inc
Sector
Industry
Phone
443-776-3133
Address
601 21ST STREET, SUITE 300, VERO BEACH
Compare PCSA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCSA
Processa Pharmaceuticals Inc
|
0.2103 | 11.96M | 0 | -11.53M | -11.12M | -4.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-24 | Initiated | H.C. Wainwright | Buy |
Processa Pharmaceuticals Inc Stock (PCSA) Latest News
Combining price and volume data for Processa Pharmaceuticals Inc.Quarterly Profit Review & Low Risk High Win Rate Stock Picks - newser.com
Published on: 2025-09-22 15:16:15 - newser.com
Can machine learning forecast Processa Pharmaceuticals Inc. recoveryQuarterly Earnings Report & Real-Time Volume Trigger Notifications - newser.com
Is now a turning point for Processa Pharmaceuticals Inc.Weekly Stock Recap & AI Driven Price Predictions - newser.com
Momentum divergence signals in Processa Pharmaceuticals Inc. chart2025 Key Highlights & High Return Stock Watch Alerts - newser.com
Strategies to average down on Processa Pharmaceuticals Inc.July 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Tools to assess Processa Pharmaceuticals Inc.’s risk profile2025 Investor Takeaways & Community Consensus Picks - newser.com
Best data tools to analyze Processa Pharmaceuticals Inc. stockInsider Selling & Long-Term Capital Growth Ideas - newser.com
Heatmap analysis for Processa Pharmaceuticals Inc. and competitors2025 Retail Activity & Target Return Focused Stock Picks - newser.com
Market Fear: Is Achieve Life Sciences Inc. benefiting from interest rate changesMarket Volume Report & Real-Time Sentiment Analysis - khodrobank.com
ETF Watch: Is USA Rare Earth Inc stock forming a cup and handleEarnings Trend Report & Real-Time Chart Breakout Alerts - خودرو بانک
Risk Hedge: Does Processa Pharmaceuticals Inc align with a passive investing strategyDay Trade & Free Long-Term Investment Growth Plans - خودرو بانک
Risk Off: Can VerifyMe Inc sustain its profitabilityMarket Trend Review & Verified Short-Term Plans - خودرو بانک
Using RSI to spot recovery in Processa Pharmaceuticals Inc.July 2025 Review & Capital Efficiency Focused Strategies - newser.com
Processa Pharmaceuticals Inc. stock trend outlook and recovery pathMarket Rally & Weekly Top Stock Performers List - newser.com
Stock Recap: Is Processa Pharmaceuticals Inc likely to announce a buyback2025 Volume Leaders & Risk Controlled Daily Trade Plans - khodrobank.com
Visual analytics tools that track Processa Pharmaceuticals Inc. performancePortfolio Return Report & High Accuracy Swing Entry Alerts - newser.com
Market Catalysts: Is Processa Pharmaceuticals Inc. stock overvalued or fairly pricedQuarterly Profit Report & Technical Buy Zone Confirmations - خودرو بانک
Aug Movers: What is Processa Pharmaceuticals Incs valuation compared to sectorRate Hike & Expert Approved Momentum Trade Ideas - خودرو بانک
Sector ETF performance correlation with Processa Pharmaceuticals Inc.July 2025 Outlook & Comprehensive Market Scan Reports - newser.com
Macro Review: Does Nkarta Inc have declining or rising EPSJuly 2025 Weekly Recap & Fast Moving Market Watchlists - خودرو بانک
Treasury Yields: Can Processa Pharmaceuticals Inc maintain sales growthJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - خودرو بانک
Profit Recap: Whats the analyst consensus on Dragonfly Energy Holdings CorpWeekly Investment Recap & High Return Stock Watch Alerts - khodrobank.com
FOMO Trade: Is Quad Graphics Inc subject to activist investor interestM&A Rumor & Risk Managed Investment Signals - خودرو بانک
Market Wrap: How much upside does TIVC haveJuly 2025 Price Swings & Weekly Market Pulse Alerts - خودرو بانک
Aug Rallies: Is Processa Pharmaceuticals Inc showing insider buyingWeekly Profit Summary & Entry Point Confirmation Alerts - خودرو بانک
Insider Buy: What is Processa Pharmaceuticals Incs valuation compared to sectorGap Up & Low Risk High Reward Ideas - خودرو بانک
Weekly Earnings: Should value investors consider Processa Pharmaceuticals IncPortfolio Return Summary & Free Community Consensus Stock Picks - خودرو بانک
Processa Pharmaceuticals Reschedules Special Shareholder Meeting - MSN
Short Interest in Heatwurx Inc. (NASDAQ:PCSA) Rises By 56.8% - Defense World
Reversal Confirmed Processa Pharmaceuticals Inc. Stock Rallies Above MAJuly 2025 Closing Moves & Verified Swing Trading Watchlist - beatles.ru
Visual trend scoring systems applied to Processa Pharmaceuticals Inc.Insider Buying & Comprehensive Market Scan Insights - Newser
Is Processa Pharmaceuticals Inc. trending in predictive chart models2025 Top Gainers & Verified Momentum Stock Alerts - Newser
How high can Processa Pharmaceuticals Inc. stock goJuly 2025 News Drivers & Accurate Entry and Exit Point Alerts - Newser
Processa Pharmaceuticals Inc. Hits Price Floor — Bounce IncomingDip Buying & Weekly Watchlist of Top Performers - beatles.ru
Combining machine learning predictions for Processa Pharmaceuticals Inc.Market Movement Recap & Free Weekly Watchlist of Top Performers - Newser
How to forecast Processa Pharmaceuticals Inc. trends using time seriesWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - Newser
Is it time to cut losses on Processa Pharmaceuticals Inc.Quarterly Profit Review & Real-Time Stock Entry Alerts - Newser
Historical volatility pattern of Processa Pharmaceuticals Inc. visualizedBuy Signal & Community Verified Trade Alerts - Newser
Exit strategy if you’re trapped in Processa Pharmaceuticals Inc.July 2025 Action & Weekly Breakout Watchlists - Newser
Bollinger Bands Show Potential Breakout in Processa Pharmaceuticals Inc.Portfolio Risk Summary & Target Return Focused Picks - beatles.ru
Is Processa Pharmaceuticals Inc. stock bottoming outJuly 2025 Sentiment & Safe Entry Point Alerts - Newser
Processa Pharmaceuticals Inc Stock (PCSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Processa Pharmaceuticals Inc Stock (PCSA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ng George K | Chief Executive Officer |
Jan 27 '25 |
Buy |
0.80 |
87,200 |
69,542 |
87,200 |
| Young David | Pres. Research & Development |
Jan 27 '25 |
Buy |
0.80 |
124,500 |
99,289 |
205,405 |
| Lin Patrick | Chief Business - Strategy Off |
Jan 27 '25 |
Buy |
0.80 |
43,500 |
34,691 |
43,500 |
1.30%
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):